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SUMMARY
Inflammation during neonatal brain infections leads to significant secondary
sequelae such as hydrocephalus, which often follows neonatal sepsis in the devel-
oping world. In 100 African hydrocephalic infants we identified the biological
pathways that account for this response. The dominant bacterial pathogen was
a Paenibacillus species, with frequent cytomegalovirus co-infection. A proteoge-
nomic strategy was employed to confirm host immune response to Paenibacillus
and to define the interplay within the host immune response network. Immune
activation emphasized neuroinflammation, oxidative stress reaction, and extra-
cellular matrix organization. The innate immune system response included
neutrophil activity, signaling via IL-4, IL-12, IL-13, interferon, and Jak/STAT path-
ways. Platelet-activating factors and factors involved with microbe recognition
such as Class I MHC antigen-presenting complex were also increased. Evidence
suggests that dysregulated neuroinflammation propagates inflammatory hydro-
cephalus, and these pathways are potential targets for adjunctive treatments to
reduce the hazards of neuroinflammation and risk of hydrocephalus following
neonatal sepsis.
INTRODUCTION
Hydrocephalus is a severe brain disorder in children (Isaacs et al., 2018; Dewan et al., 2018) and the most
common indication for pediatric neurosurgery worldwide (Simon et al., 2008). Globally, the most frequent
antecedent of hydrocephalus is infection such as neonatal or infant sepsis (Warf, 2005). Postinfectious hy-
drocephalus (PIH) accounts for up to 60% (Warf and East African Neurosurgical Research, 2010) of the
nearly 400,000 infants who develop hydrocephalus each year, principally in low- and middle-income coun-
tries (Dewan et al., 2018). Strategies to prevent PIH have been thwarted for two principal reasons. First, the
key pathogens responsible for the underlying infections that precede PIH are rarely identified and thus
treatment of the underlying infections cannot be optimized (Sinnar and Schiff, 2020). Second, we have
not identified the specific underlying inflammatory response that causes the hydrocephalus (McAllister
et al., 2015; Karimy et al., 2020). Despite recent clinical efforts to optimize surgical treatment (Kulkarni
et al., 2017), the outcomes of treatment for PIH early in life remains disappointing (Sinnar and Schiff,
2020; McAllister et al., 2015; Karimy et al., 2020). Characterizing the inflammatory responses that create
PIH is necessary to develop adjunctive strategies that can reduce the likelihood of subsequently devel-
oping hydrocephalus.
The underlying pathogenic basis for PIH can be complex. A recent pan-microbial approach uncovered Pae-
nibacillus spp. as a PIH pathogen associated with severe ventriculitis in a cohort of Ugandan children (Paul-
son et al., 2020). However, there were also frequent co-infections with cytomegalovirus (CMV). It is unclear
whether the bacteria or virus dominates the inflammatory response or whether they act synergistically. To
unravel the immune contributions from multiple pathogens, we performed whole transcriptome and pro-
tein mass spectrometry of cerebrospinal fluid (CSF) from 64 infants with PIH and 36 control non-postinfec-
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(Paulson et al., 2020; Rohlwink et al., 2019; Morales et al., 2012). Matching deep-scale proteomics (i.e., high
gene coverage) with transcriptomics (Nesvizhskii, 2014; Zhang et al., 2014) enabled optimal characteriza-
tion of the host response (Figure 1).
RESULTS
Patient characteristics
A total of 100 patients (64 PIH, 36 NPIH), all 3 months of age or less and with weight greater than 2.5 kg,
were recruited. Infants with PIH had either a history of febrile illness and/or seizures preceding the onset
of hydrocephalus or alternative findings such as imaging and endoscopic results indicative of prior ventri-
culitis (septations, loculations, or deposits of debris within the ventricular system). None of the infants with
PIH had a history of hydrocephalus at birth. Patients with NPIH had findings of hydrocephalus that was of
non-infectious origin on computed tomography (CT) or at endoscopy, including a structural cause (obstruc-
tion of the aqueduct of Sylvius, Dandy-Walker cyst, or other congenital malformation) or evidence of hem-
orrhage (bloody CSF). Before CSF acquisition, none of the 100 patients had undergone surgery on the
nervous system (reservoirs, shunt, third ventriculostomy, or myelomeningocele closure), or had evidence
of communication between the nervous system and skin such asmeningocele, encephalocele, dermal sinus
tract, or fistula.
CSF samples acquired directly from the cerebral ventricles of all patients during surgical treatment of
hydrocephalus (shunt insertion or endoscopic treatment) in Uganda were placed into cryotubes with
DNA/RNA preservative (DNA/RNA Shield, Zymo Corp). Samples were then frozen in either liquid nitro-
gen or at 80C and shipped cryogenically to the United States for further processing. Previous 16S
rRNA sequencing had recovered Paenibacillus spp. from 59% of the infants with PIH in this study, of
which 8 and 27 patients also had human herpesvirus 5 (CMV) in the CSF and blood (Paulson et al.,
2020), respectively. These previous findings directed stratification of our patients into ‘‘Paeni-positive’’
or ‘‘Paeni-negative,’’ ‘‘CMV-CSF-positive’’ or ‘‘CMV-CSF-negative,’’ and ‘‘CMV-blood-positive’’ or
‘‘CMV-blood-negative.’’ Comparison of demographic and clinical attributes between Paeni-positive
and Paeni-negative patients showed that Paeni-positive patients had higher white blood cell (WBC)
Figure 1. Schematic of proteogenomics experimental and data analysis workflow
Output data from concurrent proteomics and RNA-seq on the same samples were preprocessed, normalized, batch-
controlled, and explored independently. Differentially expressed transcriptomic and proteomic data were integrated
following dimension reduction and feature selection. Gene ontology enrichment was evaluated and common reactome
pathways were visualized to identify prominent molecular pathways implicated in the pathophysiology of postinfectious
hydrocephalus. Adapted from ‘‘PTMScan Workflow,’’ by BioRender.com (2021). Retrieved from https://app.biorender.
com/biorender-templates.
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counts in peripheral blood (11.9 versus 9.3 3 103/mL, p = 0.002) and CSF (71.6 versus 5.0 3 103/mL, p <
.001), and lower blood hemoglobin levels (10.8 g/dL versus 12.0 g/dL, p = 0.039) than those of Paeni-
negative patients. There were no significant differences in age or gender between the groups (Table 1).
Protein expression
Tandem mass spectrometry (MS/MS) spectra obtained from a standard 10-channel peptide mass tagging
(TMT-10) system and compared with the current UniRef database yielded quantitative proteomic data
(Mertins et al., 2018; Chen et al., 2012; McAlister et al., 2012; Morales et al., 2012). Median values of peptide
intensities were assigned to unique proteins and were used to infer relative protein abundances. Peptide
identifications that are non-unique by the principle of parsimony were excluded from protein quantification
(Koskinen et al., 2011). Batch effects were corrected, and intensity values were quantile normalized. Multi-
dimensional scaling (MDS) analysis demonstrated the clustering of infants with PIH and NPIH and distin-
guished Paeni-positive from Paeni-negative patients (Figure 2A). Of 616 proteins identified, 292 were
differentially expressed based on Paenibacillus spp. status: 144 and 148 proteins were up- or downregu-
lated in the Paeni-positive group, respectively (Figure 2B). Gene set enrichment analysis of the differentially
expressed proteins identified that the predominant enriched functions were involved in neuroinflamma-
tion, particularly neutrophil-mediated inflammation, negative regulation of proteolysis and peptidase ac-
tivity, and modulation of extracellular matrix and structure (Figure 2C).
RNA expression
Gene read counts (25 million reads per sample) were aggregated from expression levels estimated from
paired-end RNA sequencing (RNA-seq) data mapped to the human reference genome hg38 with STAR
and quantified with RESM (Table S1) (Dobin et al., 2013; Li and Dewey, 2011; Paulson et al., 2017). Expres-
sion of at least 1 count per million in a minimum of 18 samples was required for inclusion in the analysis.
MDS analysis demonstrated the clustering of infants with PIH and NPIH (Figure 3A). Of 11,114 genes,
2,161 were differentially expressed, and the hierarchical clustering of differentially expressed genes distin-
guished Paeni-positive from Paeni-negative patients (Figure 3B). Gene ontology analysis of the differen-
tially expressed genes based on Paenibacillus spp. status demonstrated enrichment for genes predomi-
nantly related to response to bacteria, host immune regulation, cell motility, migration, and adhesion
(Figure 3C).
Differential expression analysis of long non-coding genes
When aligning RNA, we detected 116 long non-coding RNAs (lncRNAs), out of 1,220 lncRNAs annotated in
Ensembl. Of the 116, 70 had at least one count (read) in at least 20% of the samples. Ninety samples had at
least one lncRNA present. The five most highly expressed lncRNAs were OIP5-AS1, FAM211A-AS1,
Table 1. Demographics and clinical characteristics of patients based on Paenibacillus spp. status
All patients n = 100
Paeni-negative n = 62 Paeni-positive n = 38
NPIH n = 36 PIH n = 26 PIH n = 38
Age in days, mean (SD) 57 (24) 43 (27) 75 (11) 59 (17)
Sex
Male (%) 51 (51) 16 (44) 14 (54) 21 (55)
Female (%) 49 (49) 20 (56) 12 (46) 17 (45)
Positive CMV status
Blood 27 9 8 10
CSF 8 0 2 6
CSF WBC [1.0 3 103]/mL, mean (SD) 30 (62) 5 (0.5) 5 (0.0) 72 (86.0)
Peripheral blood WBC [1.0 3 103]/mL,
mean (SD)
10.3 (3.6) 8.8 (2.6) 9.8 (3.0) 11.9 (4.1)
Hemoglobin g/dL, mean (SD) 11.5 (2.2) 13.0 (2.8) 10.5 (1.3) 10.8 (1.3)
Hematocrit %, mean (SD) 36.8 (7.4) 41.6 (9.3) 33.6 (4.2) 34.4 (4.1)
CSF, cerebrospinal fluid; CMV, cytomegalovirus; PIH, postinfectious hydrocephalus; NPIH, non-postinfectious hydrocephalus; Paeni positive, CSF Paenibacillus
spp.-positive; Paeni-negative, CSF Paenibacillus spp. negative.
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C1orf132, LINC00963, and ZNF518A. The most variable lncRNAs included OIP5-AS1, FAM211A-AS1,
C1orf132, LINC00963, as well as FAM157C. In performing differential expression, we identified 35 lncRNAs
significantly associated with Paeni-positive samples with a threshold of false discovery rate <0.05. In
A
































































































































Figure 2. Proteomic profile of infants with postinfectious hydrocephalus (PIH) and those without (NPIH), based on 16s rRNA-determined
Paenibacillus spp. status
(A) Multidimensional scaling of normalized protein abundances demonstrating clustering of Paenibacillus spp.-positive (Paeni-positive) infants from the
remaining groups. The abscissa and ordinate of the scatterplot of individual participants represent the first and second components, respectively. Each oval
(not drawn to scale) encircles majority of patients belonging to the color-matched group, with blue as infants in the NPIH group, red as Paeni-negative PIH
infants, and green as Paeni-positive infants.
(B) Volcano plot demonstrating differential expression of genes between Paeni-positive and Paeni-negative infants. Adjustment for cytomegalovirus status
did not change the differential expressions between groups. The vertical lines crossing the positive and negative abscissae demarcate fold changes of 1 and
-1, respectively, and the horizontal dashed line crosses the ordinate at the alpha significance level of 0.05. Each point represents a differentially expressed
protein, and those with an absolute fold change greater than 1 that met the significance level (red points) were selected for gene set enrichment analyses.
Genes with enrichment below the statistically significant threshold are displayed in gray.
(C) Gene ontology analyses of differentially expressed proteins of infants based on 16s rRNA-determined Paenibacillus spp. status. There was enrichment for
functions associated with neuroinflammation, extracellular matrix structure, and cell-cell adhesion among Paeni-positive infants compared with Paeni-
negative infants. The abscissae (ratio) of the dot plots correspond to the number of proteins per total number of proteins, and the size of each circle reflects
the relative number of proteins expressed that are enriched for the corresponding function (ordinates).
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Paeni-positive samples, the lncRNAs with the largest fold-changes (upregulation) were FAM157C, SPA-
CA6P, LINC00243, LINC01128, and SEMA3B. No lncRNAs were significantly downregulated in Paeni-pos-
itive samples. The nature of how these lncRNAs are associated with disease and Paenibacillus spp. positiv-
ity will be of future interest.
Role of CMV co-infection
Adjusting for CMV status at the transcriptome level did not significantly alter the results of the gene
ontology enrichment analysis based on Paenibacillus spp. positivity. Sixty-four genes were differentially ex-
pressed based on CMV status, and those genes were enriched for functions related to host response to
virus (Figure 4A). Principal-component analysis (PCA) using RNA abundance of all genes was not able to
cluster samples by CMV status (Figure 4B). Adjusting for CMV status on proteomic data did not change
the differentially abundant proteins (Figure 4C).
Network correlation analysis was employed to identify sets of genes that share a pattern of expression
among patient RNA data. First, a subset of patients was identified using hierarchical clustering based
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Figure 3. Transcriptomic profile of infants with postinfectious hydrocephalus (PIH) and those without (NPIH), based on 16s rRNA-determined
Paenibacillus spp. status
(A) Multidimensional scaling of normalized gene expression demonstrating clustering of Paenibacillus spp.-positive (Paeni-positive) infants from the
remaining groups. The abscissa and ordinate of the scatterplot of individual participants represent the first and second components, respectively. Each oval
(not drawn to scale) encircles the majority of patients belonging to the color-matched group, with blue as infants in the NPIH group, red as Paeni-negative
PIH infants, and green as Paeni-positive infants.
(B) Heatmap of the 500 most differentially expressed genes between the Paeni-positive and Paeni-negative infants, with the dendrogram demonstrating
hierarchical clustering on Euclidean distance of gene identified in infants based on Paenibacillus spp. status.
(C) Gene ontology analyses of differentially expressed genes of infants based on 16s rRNA-determined Paenibacillus spp. status. There was enrichment for
functions associated with neuroinflammation, extracellular matrix structure, and cell-cell adhesion among Paeni-positive infants compared with Paeni-
negative infants. The abscissae (ratio) of the dot plots correspond to the number of proteins per total number of proteins, and the size of each circle reflects
the relative number of proteins expressed that are enriched for the corresponding function (ordinates).
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patients. Then, using Weighted Correlation Network Analysis (WGCNA), two gene sets (Modules 1 and 2)
were identified as having similar patterns of expression within this subset of 33 patients (Table S2). These
modules were assessed for network correlation with four clinical variables: CSF and peripheral blood
WBC counts, Paenibacillus spp. status, and CSF CMV status (Figure 5A). Module 1 contained all but 27
of the 2,205 genes differentially expressed with respect to Paenibacillus spp. status. This module corre-
lated positively with CSF cell count and negatively with Paenibacillus spp. status. Genes in Module 1 were
enriched for functions related to host immune response (Figure 5B). Module 2 was positively correlated
with Paenibacillus spp. status, but the 27 genes included in this module were not enriched for any gene
ontologies, indicating no specific functional enrichment for the small number of genes within this module.
Marker genes of bulk RNA sequencing
Patient bulk RNA expression was analyzed for immune cell-type signatures using reference single-cell RNA
sequencing data (Figure 5C). The R package xCell identifies cell type proportions within bulk RNA
sequencing data based on enrichment of marker gene expression (Aran et al., 2017). Upon hierarchical
clustering, two groups were evident: a mixture of PIH and NPIH samples with a predominance of hemato-
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Figure 4. Role of CMV co-infection
(A) An interactome of the 64 genes that were differentially expressed based on CMV status, enriched for functions related to host response to virus.
(B) Principal-component analysis plot demonstrating that using RNA abundance of all genes was not able to cluster samples by CMV status. The abscissa and
ordinate of the scatterplot of individual participants represent the first and second components, respectively.
(C) Volcano plot demonstrating there are no differentially expressed proteins based on CMV status alone (blue points) that had a fold change greater than 1
or met statistical significance criteria. Genes with enrichment below the statistically significant threshold are displayed in gray. Differential expression of
proteins based on Paenibacillus spp. status was similar with or without adjusting for CMV status (Figure 2).
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Integration of proteomics and transcriptomics data was performed following dimension reduction and
feature selection of differentially expressed proteins and genes. Unsupervised gene ontology analyses
of the concatenated data recapitulated enrichment for functions related to the immune system, meta-
bolism, response to oxidative stress, cell-cell junction interactions, and extracellular matrix structure in as-
sociation with peptidase activity (Figure 6A).
There were 33 genes detected by both proteomics and RNA-seq as significant; infants with Paeni-positive
PIH had consistently differing counts of those markers than did the Paeni-negative infants and infants with
NPIH (Figure 6B). Pathway enrichment analysis of those genes demonstrated a predominance of functions
associated with the immune system, particularly those involved with interleukin (IL)-4, IL-12, IL-13, inter-
feron, and neutrophil activity, as well as those relating to Janus kinase/signal transducers and activators
of transcription (Jak/STAT) pathway. In addition, there was enrichment for processes involving response
to platelet-activating factors and host recognition of microbes including antigen presentation and Class
I major histocompatibility complex (MHC) antigen processing (Figure 7, Table S3).
DISCUSSION
Disease pathogenesis involves the combinatorial interaction of the proteome, transcriptome, and environ-
ment (Rédei, 2008; Heintzman and Ren, 2006). By matching deep-scale proteomics (i.e., high gene
coverage) with transcriptomics (Nesvizhskii, 2014; Zhang et al., 2014), the interplay within the host immune
response can be optimally reduced into network models representing disease (Ruggles et al., 2017).
In this study, genes with differential mRNA or protein abundance among patients with PIH were enriched
for functions related to neuroinflammation, reaction to oxidative stress, cell-cell junction structure, and
A C
B
Figure 5. Weighted correlation network analysis (WGCNA) and single-cell RNA deconvolution
(A) Gene modules within RNA-seq data for PIH and NPIH cohorts identified by WGCNA. Module 1 positively correlated with CSF cell count and negatively
with Paenibacillus spp. status and was enriched for host immune responses, including leukocyte and neutrophil functions. (B) Module 2 was positively
correlated with Paenibacillus spp. status, but the associated genes had no specific functional enrichment.
(C) Deconvolution of bulk RNA data into immune cell populations expressed on a scale of 0 to 1 that is calculated for each patient. There was hierarchical
clustering of a mixture of NPIH and PIH samples with a hematologic predominance, and PIH-only samples with T helper and NK cell populations.
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extracellular matrix organization. Combining proteomics and RNA-seq results narrowed the spectrum of
responses to the innate immune system, including neutrophil activity and signaling via IL-4, IL-12, IL-13,
interferon, and Jak/STAT pathways, in addition to platelet-activating factors. Furthermore, there was
enrichment for factors involved with microbe recognition such as Class I MHC antigen-presenting complex.
Our findings are consistent with a major role for up-regulation of genes and proteins associated with
neutrophil activation. Nevertheless, in addition to the direct role in fighting the infection, we note that there
appears to be substantial concomitant parenchymal loss in these patients, and we cannot rule out innate-
immunity-mediated tissue damage caused by this immune response. One of the difficulties of ascribing
infection causality to the presence of pathogen genomes is the ubiquitous problem of environmental
and reagent contamination in low-biomass samples, the sensitivity of sequencing techniques, the potential
artifacts and biases contributed by sequence amplification when investigating bacterial 16S, as well as the
presence of microbes within nominally sterile body spaces that may not be causing active infection. Our
findings demonstrated a patterned innate immune response associated with the presence of Paenibacillus
16S DNA that strengthens the causal association of Paenibacilluswith infection. In light of the recent conflu-
ence of evidence suggesting that dysregulated neuroinflammation propagates inflammatory hydroceph-
alus (including PIH and post-hemorrhagic, PHH post-hemorrhagic) (Karimy et al., 2020; Warf, 2005), the
pathways we identified are potential targets for adjunctive treatments to reduce the hazards of neuroin-
flammation and risk of hydrocephalus following neonatal sepsis.
Figure 6. Proteogenomic integration of proteins and genes expressed in RNA-seq and/or proteomics among
infants with postinfectious and non-postinfectious hydrocephalus stratified by cerebrospinal fluid 16s rRNA
Paenibacillus spp. status
(A) Alluvial plot demonstrating the most prominent gene ontological (GO) functions and interactions for PIH
pathophysiology between Paenibacillus spp.-positive and Paenibacillus spp.-negative infants. Each ontological
clustering occupies a column in the diagram and is horizontally connected to preceding and succeeding significance
clustering by stream fields, representing similar gene involvement. Each stacked bar is color-coded based on the assay
being assessed, with red representing RNA-seq data, purple for proteomics, and green for genes common to both RNA-
seq and proteomics. The ordinate shows the number of genes represented in each cluster.
(B) Box and whisker plot of the 33 genes that were differentially expressed based on Paenibacillus spp. status. Counts
(ordinate) of each gene (abscissa) are shown for each group, with blue representing NPIH, red for Paeni-negative PIH, and
green for Paeni-positive PIH infants.
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Host immune responses in PIH
In addition to ventriculomegaly (enlargement of the cerebral ventricles), the PIH phenotype is character-
ized by CSF fluid loculations, debris within fluid spaces, ectopic calcification, and brain abscesses (Ciurea
et al., 2005), suggesting that severe inflammation occurs locally during the antecedent neonatal sepsis.
Typically, once a pathogen breaches a host’s endothelial and epithelial barriers, immune responses are
activated. Although there is a rapid accumulation of immunologic competence after birth, the innate
immune system is the primary active defense for infants less than 3 months of age, since they lack the anti-
genic experience that informs acquired immunity. Consequently, the neonatal host immune response in-
volves antigen-independent immune components such as neutrophils, phagocytes, NK cells, and anti-
gen-presenting cells (Bell, 2003; Kawai and Akira, 2006; Villarino et al., 2017; PrabhuDas et al., 2011;
Ygberg and Nilsson, 2012). Our RNA-seq immune cell signature analyses support the role of NK cells in
the host response of patients with PIH. The toll-like receptor (TLR) immune system pathway is commonly
implicated in post-inflammatory (including infectious or hemorrhagic) hydrocephalus (Karimy et al.,
2017, 2020; Sokol et al., 2016; Lattke et al., 2012); however, the cytokine- and interferon-induced Jak/
STAT pathway is considered the most efficient form of innate immunity, especially with intracellular path-
ogens (Villarino et al., 2017; O’Shea et al., 2015). Protein mutations in the Jak/STAT pathway have been
implicated in inadequate inflammation mediation (Villarino et al., 2017; O’Shea et al., 2015). For example,
impaired Jak function in severe combined immunodeficiency is associated with susceptibility to infections
due to the absence of NK, B, or T cells (Noguchi et al., 1993, 2008). At the protein and transcript levels, we
observed differential expression of factors associated with interleukins (IL-4, IL-12 and IL-13) and interferon
activity, both of which are obligate mediators of the Jak/STAT pathway (Villarino et al., 2017; O’Shea et al.,
2015). Upregulation of MHC Class I in our cohort could be an indication of presentation to cytotoxic CD8+
cells and IL-12 activity (Adiko et al., 2015).
Inflammation and barrier integrity in PIH
The activated immune pathways found in PIH support the perspective that the neonatal immune response
to infection or hemorrhage leads to ependymal gliosis or denudation, scarring of CSF conduits, and disrup-
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Figure 7. Pathway analysis of 33 genes that were differentially expressed in both RNA-seq and proteomics among infants with postinfectious and
non-postinfectious hydrocephalus stratified by cerebrospinal fluid 16s rRNA Paenibacillus spp. status
Corresponding pairs of upregulated (red boxes) and downregulated (green boxes) proteins (blue columns) and genes (purple columns) in the Paenibacillus
spp.-positive group that were identified with proteomics and RNA-seq, respectively, are listed on the abscissa. The 33 common genes demonstrated
predominant involvement of the immune system, particularly the innate system and those associated with neutrophil-mediated activity, interleukins,
interferon, and the Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway (ordinate). Differential expression was defined as log2
fold change of >1 or < -1 at an alpha significance level of 0.05.
ll
OPEN ACCESS
iScience 24, 102351, April 23, 2021 9
iScience
Article
fighting infection and clearing microbial pathogens, prolonged or overstimulated immune activation may
be detrimental (Tchessalova et al., 2018); indeed, recent evidence from both experimental (Guerra et al.,
2015a; Ortloff et al., 2013; Rodriguez et al., 2012; Jimenez et al., 2009; Paez et al., 2007; Batiz et al.,
2005) and clinical (Ortega et al., 2016; Guerra et al., 2015a; Sival et al., 2011) studies demonstrates that
host immune response associated with ependymal cell-cell junction protein disruption is a critical patho-
genetic mechanism of hydrocephalus.
We also observed platelet-activating factors and response to reactive oxidative species. Elevations in
platelet-activating factors have been associated with compromise of the blood-brain barrier (Brailoiu
et al., 2018), and their signaling pathways are an important link between inflammatory and thrombotic pro-
cesses, including in sepsis (de Oliveira et al., 2017; Yost et al., 2010; Pun et al., 2009). Reactive oxygen spe-
cies set off a cascade of cellular excitotoxicity and secondary brain injury that impairs brain oxygenation
and perpetuates cerebral vascular dysfunction (Lehner et al., 2011). Such vascular pathology is consistent
with our finding of a differential expression of factors involved in platelet activity including PFN1, ITIH4, and
A2M.
Potential pathologic overlap with NPIH
Inflammation is a component of other forms of hydrocephalus (Habiyaremye et al., 2017; Karimy et al.,
2017), which informed our decision to use noninfectious hydrocephalic infants as controls. In a recent re-
view, Karimy et al. discussed evidence that PIH shares common host immune pathways with PHH (Karimy
et al., 2020). In our PIH cohort, we identified upregulation of IL-12 signaling, which is typically involved in
augmentation of CD8+ T cell cytotoxicity. PHH is also associated with significantly elevated levels in other
cytokines including IL-1, IL-10, CCL-3, and CCL-13 (Habiyaremye et al., 2017). Neuroinflammation has been
linked to the ependymal barrier damage found in humans and several experimental models of hydroceph-
alus (McAllister et al., 2017). Such ependymal damage was shown to result from cleavage of cell adhesion
proteins (McAllister et al., 2017; Castaneyra-Ruiz et al., 2018). Indeed, many forms of human congenital
hydrocephalus result from genetic alterations of proteins involved in cell-cell junctional integrity including
N-cadherin, connexin, and L1CAM (Guerra et al., 2015b), which are critical for the differentiation of the ven-
tricular and subventricular zone neural stem cells into mature ependyma (Jin et al., 2020). In addition, a
recent exome sequencing of 381 infants with congenital hydrocephalus identified a predominance of de
novo mutations in genes associated with neural stem cell differentiation (Jin et al., 2020). Experimentally,
a series of studies on hyhmice (Jimenez et al., 2009; Batiz et al., 2005, 2006; Perez-Figares et al., 1998; Wag-
ner et al., 2003) that develop perinatal aqueductal stenosis also support the concept of a defect in cell junc-
tion complexes as an underlying cause of hydrocephalus. Although our use of NPIH as controls focused on
the acute inflammatory responses that lead to PIH, there are linkages to common mechanisms in other
forms of infant hydrocephalus.
Role of immunomodulation for PIH prevention
It would be premature to suggest that our findings support the use of anti-inflammatory or immunosup-
pressive agents during neonatal sepsis to mitigate the risk of developing hydrocephalus. There have
been many attempts to use corticosteroids in treating infants with acute bacterial meningitis; but except
for some notable exceptions such as Haemophilus influenza (Schaad et al., 1993; Syrogiannopoulos
et al., 1994; King et al., 1994; Wald et al., 1995; Kilpi et al., 1995) and pneumococcal meningitis (Kanra
et al., 1995; Kilpi et al., 1995; King et al., 1994; Schaad et al., 1993; Syrogiannopoulos et al., 1994; Wald
et al., 1995), there have been many failures with some devastating outcomes (Kanra et al., 1995; Kilpi
et al., 1995; King et al., 1994; Lebel et al., 1988, 1989; Odio et al., 1991; Syrogiannopoulos et al., 1994)
and this remains an area of controversy (Schaad et al., 1995; McIntyre et al., 1997; Coyle, 1999; Goodman
et al., 2002). Our work points to critical intervention pathways and suggests that selective and targeted
modulation of aspects of the immune response might be studied when treating brain infections to prevent
hydrocephalus. For example, in addition to pro-inflammatory immune factors, we found differential expres-
sion of IL-4 and IL-13, which generally have anti-inflammatory effects. IL-4 and IL-13 can share a common
receptor (Hilton et al., 1996; Jiang et al., 2000; Callard et al., 1996) and typically work synergistically to
decrease inflammation by counteracting the activity of pro-inflammatory cytokines such as IL-12 (Minty
et al., 1993; Mori et al., 2016). IL-4 and IL-13 are also considered neuroprotective as they can induce death
of microglial cells that mediate neuronal damage (Won et al., 2013; Deboy et al., 2006; Yang et al., 2002).
However, IL-4 and IL-13 can potentiate oxidative stress-related injury to neurons (Nam et al., 2012;
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Park et al., 2008). Thus, one possibility is that the balance of IL-12 and IL-4/IL-13 within the CSF contributes
to risk of PIH, implying that their targeted modulation is a potential therapeutic target.
Viral co-infection in PIH
Identifying CMV in the CSF of a subset of infants in our cohort (Paulson et al., 2020) raises the important
question of whether the host immune response was in part attributable to CMV. Although there were differ-
entially expressed transcripts detected in CSF consistent with the host response to central nervous system
viral infection in CMV-positive infants, we did not detect any functional proteins associated with a response
to CMV nor was there any effect of CMV status on the differential expression of host immune markers at the
protein level. This may be due to our small sample size (8/100 CSF and 27/100 blood) of CMV-positive in-
fants, or the ability of the virus to modulate protein synthesis in the host (Marshall and Geballe, 2009). Alter-
natively, CSF CMV status using PCR underestimates CMV burden as intracellular CMV may be difficult to
detect in CSF samples with low cell counts, and because CMV cycles through latent and active states in
affected individuals (Cheeran et al., 2009). It remains unclear whether CMV was a risk factor for developing
PIH or whether the presence of this virus will have long-term effects in these infants.
Conclusions
Inflammation following neonatal infection is a dominant cause of childhood hydrocephalus. An integrated
proteogenomic strategy identified gene pathways involving the innate immune system, cell-cell junction
structure, platelet activation, and microbial recognition in African infants with PIH. These findings enable
the development of preventive hydrocephalus risk reduction strategies during the treatment of neonatal
sepsis.
Limitations of the study
Limitations to this study include small cohort size for subset analyses such as CMV-positive participants and
low RNA abundance in NPIH samples. Because NK cell activity, IL-12 signaling, and JAK/STAT pathwaymay
indicate viral immune response, it is possible that co-infection with CMV was more common in our patients
than our conservative approach to CMV detection permitted. The observation of Th2 cell activation by IL-4/
IL-13 needs confirmation in an independent cohort. In addition, attribution of RNA expression to specific
cells cannot be completed for the current samples, limiting the ability to confirm the role of specific immune
cells in PIH. Furthermore, the majority of activated gene networks identified were pathogen-stratified
based on Paenibacillus spp. presence.
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TRANSPARENT METHODS 
Study Cohort  
Participants were recruited at the CURE Children's Hospital of Uganda (CCHU), a pediatric neurosurgery 
hospital that serves as the largest referral center for patients with hydrocephalus in Uganda. Inclusion 
criteria for PIH: a) age 3 months or less, b) weight greater than 2.5 kg, c) mothers at least 18 years old to 
give informed consent, and d) no history of hydrocephalus at birth, and either: i) a history of febrile illness 
and/or seizures preceding the onset of hydrocephalus, or ii) alternative findings such as imaging and 
endoscopic results indicative of prior ventriculitis including septations, loculations, or deposits of debris 
within the ventricular system. Inclusion criteria for NPIH: a) age 3 months or less, b) weight greater than 
2.5 kg, c) absence of findings consistent with PIH or congenital origin of hydrocephalus, d) mothers at least 
18 years old to give informed consent, and e) findings of non-infectious origin of hydrocephalus on 
computed tomography (CT) scan or at endoscopy including structural cause (obstruction of the Aqueduct 
of Sylvius, Dandy-Walker cyst, aneurysm, cavernous malformation, or other congenital malformation) or 
evidence of hemorrhage (bloody CSF). Exclusion criteria for hydrocephalus study: a) prior surgery on the 
nervous system (shunt, third ventriculostomy, or myelomeningocele closure), or b) evidence of 
communication of nervous system with skin such as meningocele, encephalocele, dermal sinus tract, or 
fistula. Clinical patient information including demographics, computed tomography (CT) neuroimaging, 
CSF cell counts, and CSF culture results were obtained from review of the medical records.  
Ethics approval and consent to participate 
Ethics oversight was provided by the CCHU Institutional Review Board (IRB), Mbarara University of 
Science and Technology Research Ethics Committee, the Ugandan National Council on Science and 
Technology, and the Pennsylvania State University (PSU) IRB. Verbal informed consent was obtained from 
the mother of each subject. 
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CSF Samples  
Sterile CSF samples were acquired directly from the cerebral ventricles of all patients at the time of surgery 
(shunt insertion or endoscopic treatment) for treatment of hydrocephalus. After collection, aliquots of each 
sample were alternately placed into either a genomic preservative (DNA/RNA Shield, Zymo Research, 
Irvine CA) to preserve DNA and RNA, or fresh frozen to preserve protein content, and maintained in liquid 
nitrogen or in a -80-degree Celsius freezer prior to cryogenic shipment, for final -80-degree Celsius storage 
until proteomics and/or RNA-Seq was performed.  
Proteomics characterization 
Sample preparation and mass spectrometry 
A standard validated proteomics workflow was utilized (Mertins et al., 2018). High abundance proteins in 
CSF (albumin, IgG, α1-antitrypsin, IgA, transferrin and haptoglobin) were first removed using a 
reproducible affinity method (Morales et al., 2012).  The depleted samples were then enzymatically digested 
with trypsin after protein denaturation, reduction and alkylation. Peptides were prepared for isobaric 
labeling using robotic solid phase extraction (Mertins et al., 2018, Chen et al., 2012). A ten-channel isobaric 
peptide mass tagging (TMT-10) was used. The purified peptides were labeled and pooled in sets of ten with 
one label used for tagging a reference pool for all sets of nine samples. The labeled reference pool was used 
for normalization and merging multiple ten plex data sets. The labeled peptides were analyzed by high-
resolution liquid chromatography-mass spectrometry (LC-MS) using a Q-Exactive Plus instrument coupled 
to an EASY-nanoLC 1000 system (Thermo-Fisher Scientific).  The pooled samples in batches of ten CSF 
patient samples were loaded onto a 75 µm i.d. × 25 cm Acclaim® PepMap 100 RP column (Thermo-Fisher 
Scientific). Peptide separations were started with 95% mobile phase A (0.1% FA) for 5 min and increased 
to 30% B (100% MeCN , 0.1% FA) over 180 min, followed by a 25-min gradient to 45% B, a 5-min gradient 
to 95% B and washed at 90% B for 7 min, with a flow rate of 300 nL/min. Full-scan mass spectra were then 
acquired using the Orbitrap mass analyzer in the mass-to-charge ratio (m/z) of 375 to 1400 and with a mass 
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resolving power set to 70,000. Fifteen data-dependent high-energy collisional dissociation (HCD) were 
performed with a mass resolving power set to 35,000, a fixed first m/z 100, an isolation width of 0.7 m/z, 
and the normalized collision energy setting of 32. The maximum injection time was 50 ms for parent-ion 
analysis and 105 ms for product-ion analysis. Target ions already selected for mass spectrometry (MS)/MS 
were dynamically excluded for 30 sec. An automatic gain control target value of 3 x 106 ions was used for 
full MS scans and 1 x105 ions for MS/MS scans. Peptide ions with charge states of one or greater than six 
were excluded from MS/MS interrogation.  
Protein identification 
MS raw data were converted to peak lists using Proteome Discoverer (version 2.1.0.81, Thermo-Fisher 
Scientific) with the integration of reporter-ion intensities of TMT 10-plex at a mass tolerance of ±3.15 mDa 
(Werner et al., 2014).  MS/MS spectra with charges +2, +3 and +4 were analyzed using Mascot search 
engine (Perkins et al., 1999)  (Matrix Science, London, UK; version 2.6.2).  Mascot was set up to search 
against a SwissProt database of human (version June 2016, 20,237 entries) and common contaminant 
proteins (cRAP, version 1.0 Jan. 1st, 2012, 116 entries), with trypsin/P set as the digestion enzyme and 
allowing for a maximum of 4 missed cleavages.  The searches were performed with a fragment ion mass 
tolerance of 0.02 Da and a parent ion tolerance of 20 ppm.  Carbamidomethylation of cysteine was specified 
in Mascot as a fixed modification.  Deamidation of asparagine, formation of pyro-glutamic acid from N-
terminal glutamine, acetylation of protein N-terminus, oxidation of methionine, and pyro-
carbamidomethylation of N-terminal cysteine were specified as variable modifications.  Peptide spectrum 
matches (PSM) were filtered at 1% false-discovery rate (FDR) by searching against a reversed database 
and the ascribed peptide identities were accepted.  The uniqueness of peptide sequences among the database 
entries was determined using the principle of parsimony.  Protein identities were inferred using a greedy 
set cover algorithm from Mascot and the identities containing  2 Occam’s razor peptides were accepted 
(Koskinen et al., 2011). 
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Protein relative quantification 
The processing, quality assurance and analysis of TMT data were performed with proteoQ (version 1.0; 
https://github.com/qzhang503/proteoQ). Reporter-ion intensities under 10-plex TMT channels were first 
obtained from Mascot, followed by removal of PSM entries from shared peptides or those with intensity 
values lower than 1E3. Intensity of PSMs were converted to logarithmic ratios at base two, relative to the 
average intensity of reference samples which bookmarked all 10-plex TMT sets.  Under each TMT channel, 
Dixon’s outlier removals were carried out recursively for peptides with greater than two identifying PSMs.  
The median of the ratios of PSM that could be assigned to the same peptide was first taken to represent the 
ratios of the incumbent peptide.  Peptide identifications that could be assigned to more than one protein 
were excluded from protein quantification. The median of the ratios of peptides were then taken to represent 
the ratios of the incumbent protein. To align protein ratios under different TMT channels, likelihood 
functions were first estimated for the log-ratios of proteins using finite mixture modelling, assuming two-
component Gaussian mixtures (Benaglia et al., 2009).  The ratio of distributions was then aligned by 
maximum likelihood of log-ratios centered at zero for each sample.  Scaling normalization was performed 
to standardize the log-ratios of proteins across samples.  To discount the influence of outliers from either 
log-ratios or reporter-ion intensities, values between the 5th and 95th percentile of log-ratios and 5th and 95th 
percentile of intensity were used for standard deviation calculations.   
Transcriptomics Characterization 
RNA Extraction 
RNA was extracted from shield samples using TRIzol™ LS Reagent and Direct-zol™ RNA MiniPrep Plus 
kit (Zymo Research, R2072). Two aliquots of 250 µl of CSF and shield mixture were added to 750 µl of 
TRIzol™ LS Reagent (Invitrogen, 10296010). After bead lysis, 200 µl of chloroform was added, incubated 
at room temperature for 15 minutes then centrifuged at 12,000 xg for 15 minutes at 4°C. Once spun down 
the aqueous layers from the two aliquots were put into the same tube. Then each organic layer was re-
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suspended in 400 µl of water then centrifuged with the same parameters again for 5 minutes. The now 1.6 
mL of aqueous phases are combined with 1.6 mL of 100% ethanol and then put through the Zymo-Spin™ 
IC Column twice and then proceeded from step two of the manufacturer’s protocol.  
RNA-Seq 
The Illumina® TruSeq® Stranded RNA Sequencing kit was used following the manufacturer’s protocol, 
which encompassed rRNA depletion and fragmentation, first strand cDNA synthesis, second strand cDNA 
synthesis, adenylate 3’ ends, adapters ligation, and DNA fragment enrichment. Due to the nature of low 
cell counts in CSF, varying concentrations of RNA were extracted from the samples (Supplemental Table 
1). Majority of the RNA concentrations fell below the recommended input of 100 ng so a standard 10 µl of 
total RNA was used for input ranging from 10-150 ng of RNA. Using biotinylated, target-specific oligos 
combined with Ribo-Zero ribosomal RNA (rRNA) removal beads of divalent cations and high temperatures 
(60 – 100oC). Ribosomal RNA was then depleted from the total RNA and the remaining RNA was purified, 
fragmented, and primed for cDNA synthesis. The cleaved RNA fragments were then copied into first strand 
cDNA using reverse transcriptase (Part # 18064-014) and random hexamers. A second strand cDNA 
synthesis was obtained by removing the RNA template, synthesizing a replacement strand, and 
incorporating dUTP in place of dTTP to generate the ds (double stranded) cDNA, using DNA Polymerase 
I and RNaseH. A single 'A' nucleotide was then added to the 3' ends of the blunt fragments and a 
corresponding single 'T' nucleotide was added on the 3' end of the adapter. Multiple indexing adapters were 
then ligated to the ends of the ds cDNA fragments to prepare them for hybridization. Polymerase chain 
reaction (PCR) was used to enrich the DNA fragments which was done without dUTP to ensure only the 
first strand was enriched. The libraries were quantified by fluorometry and size- and quality-checked on an 
Agilent Technologies 2100 Bioanalyzer. Libraries were then pooled to 4 nM, diluted and sequenced on the 
NovaSeq 6000 using the S2 flow cell with 2x100 reads aiming for 25 million reads per sample.  
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Transcriptomics data processing 
We used Trimmomatic (v0.38) to trim and crop paired-end RNA sequence adaptors and low sequencing 
score reads as quality control with default parameters. After filtering for quality control, paired-end RNA-
Seq were mapped to the human reference genome hg38 using STAR (Dobin et al., 2013). Gene and isoform 
expression levels were estimated from mapped RNA-Seq data (Li and Dewey, 2011). Read counts from all 
samples were aggregated into a matrix for further analysis. Quality measures are included in Supplemental 
Table 1. Quality control was assessed through scatterplots between log RNA input and log library size 
where we observed a weak Spearman correlation (0.39). The average and median number of reads was 36 
million and 19 million respectively. Gene expression sets from the RNASeq matrix data were normalized 
(Paulson et al., 2017), and those with expression of at least 1 count per million in a minimum of 18 samples 
were filtered for inclusion in downstream analysis. 
Data Analysis 
All analyses were performed with R v.3.5TM (http://www.R-project.org) utilizing the following packages: 
ComBat (Johnson et al., 2007), clusterProfiler (Yu et al., 2012), DESeq2 (Love et al., 2014), edgeR 
(Robinson and Smyth, 2007), Limma (Ritchie et al., 2015), RSEM (Li and Dewey, 2011), STAR (Dobin et 
al., 2013), and YARN (Paulson et al., 2017). Continuous demographic variables were evaluated using the 
non-parametric Mann-Whitney test (2-group comparisons) following Shapiro-Wilk's test for normality. 
Fisher’s exact test was performed for categorical variables. Analyses are made available in our public 
Github repository https://github.com/Schiff-Lab/iScience_Paper_Isaacs_Morton_2021. 
Transcript and protein data analyses 
Following quantile normalization and correction of batch effects (Paulson et al., 2017, Johnson et al., 2007), 
Principal component analysis (PCA) of gene expression and protein log2 ratios were performed. Log fold 
change values of the gene and protein abundances between groups were calculated by comparing mean 
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expression levels using edgeR (Robinson and Smyth, 2007)  and Limma (Szklarczyk et al., 2019) 
respectively. Genewise Negative Binomial Generalized Linear Model and Empirical Bayes Moderation 
were carried out to ensure variances were no longer dependent on mean gene or protein expression levels, 
respectively. The number of differentially expressed genes or proteins were examined with significance set 
at a false discovery rate controlled for multiple testing comparisons using the method of Benjamini and 
Hochberg (Benjamini and Hochberg, 1995)  with adjusted p-value cutoff of 0.05 and absolute log fold 
change of 1. Gene and proteins that were differentially expressed in multiple comparisons were extracted 
and examined from smallest to largest adjusted p-value with their associated log fold changes. 
clusterProfiler was then used to map differentially expressed genes and proteins to their respective Gene 
ontology (GO) terms to assess for enrichment. Clinical factors that correlate with the expression of gene 
sets were determined using the R package WGCNA. Average expression of the 2205 genes differentially 
expressed within Paenibacillus positive patient samples were used to cluster the samples, and a height cutoff 
was applied to the height of the hierarchical clustering graph to separate a cluster of 33 samples with the 
highest gene expression values. Modules of genes with expression values that correlated significantly with 
clinical factors among those 33 samples were identified. 
 
Marker genes of bulk RNA sequencing 
Filtered RNA counts generated in expression analysis were normalized as transcripts per million bases 
(TPM) values. The R package ImmuneDeconv was used to deconvolute the per-patient bulk RNA data into 
immune cell populations. Identity with immune cell populations, expressed on a scale of 0-1, was calculated 
for each patient.    
Proteogenomic integration 
Integration of proteomics and transcriptomics data was performed following dimension reduction and 
feature selection of differentially expressed proteins and genes. GO enrichment using Database for 
Annotation, Visualization and Integrated Discovery (DAVID v6.8) (Huang et al., 2009)  and reactome over-
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representation pathway analysis were performed by concatenating differentially expressed proteins and 
genes with a set absolute log2 fold change of 1 and a false discovery rate of 0.05. The integrated data were 
examined for gene/pathway/GO enrichment. Physical and functional protein-protein interactions of the 
genes common to both proteomics and RNA-Seq were assessed using the STRING (Szklarczyk et al., 2019) 
online tools. Gene-gene relationships between differentially expressed genes were quantified by assigning 
a composite score to each pairwise comparison. Each composite score reflects chromosome neighborhood, 
gene fusion, phylogenetic co-occurrence, homology, co-expression, experimentally determined 
interactions, database annotation and automated text mining between pairs of genes, and the higher the 
score (i.e., closer to 1), the stronger the predicted gene-gene relationship (Szklarczyk et al., 2019). 
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Table S1, RNA library characteristics, Related to Figure 3
Sample TotalRead UniqeMapRead UniqeMapPercent(%) MultipleMapRead MultipleMapPercent(%) MaptooManyRead MaptooManyPercent(%) RNA Input (mg)
IPM0802 73526702 2841876 3.87% 70542999 95.94% 87357 0.12% 0.119
IPM0803 22584637 1782920 7.89% 20739603 91.83% 10603 0.05% 0.553
IPM0804 33165936 1007234 3.04% 32088912 96.75% 23731 0.07% 0.488
IPM0805 17824517 4475434 25.11% 13251675 74.35% 11779 0.07% 2.04
IPM0806 19087508 3056512 16.01% 15978508 83.71% 8484 0.04% 0.262
IPM0807 19658293 597234 3.04% 19016068 96.73% 7678 0.04% 0.105
IPM0808 16833340 476522 2.83% 16310219 96.89% 5657 0.03% 0.105
IPM0809 17923971 11607911 64.76% 6109956 34.09% 20394 0.11% 3.772
IPM0811 6004333 146842 2.45% 5817240 96.88% 3484 0.06% 0.13
IPM0812 12567292 11285465 89.80% 1142589 9.09% 12796 0.10% 3.2
IPM0813 26557668 879111 3.31% 25586048 96.34% 13603 0.05% 0.009
IPM0814 20895259 500503 2.40% 20365054 97.46% 11197 0.05% 0.026
IPM0815 19745837 544408 2.76% 19170512 97.09% 9245 0.05% 0.031
IPM0816 14086428 7255898 51.51% 6677533 47.40% 15624 0.11% 0
IPM0817 21290339 535267 2.51% 20713563 97.29% 8755 0.04% 0.013
IPM0818 24442848 583117 2.39% 23775939 97.27% 38002 0.16% 0.023
IPM0819 57585259 1564100 2.72% 55777291 96.86% 142644 0.25% 0.031
IPM0820 64126950 1582687 2.47% 62355478 97.24% 104014 0.16% 0.033
IPM0821 47374670 1372740 2.90% 45878057 96.84% 77321 0.16% 0.002
IPM0822 38705264 1073660 2.77% 37526650 96.95% 57081 0.15% 0.018
IPM0823 20302717 717891 3.54% 19535396 96.22% 21250 0.10% 0.204
IPM0824 26648882 643800 2.42% 25921753 97.27% 38259 0.14% 0.027
IPM0825 31791867 813828 2.56% 30911375 97.23% 31466 0.10% 0.005
IPM0826 220730424 7850396 3.56% 212520643 96.28% 243993 0.11% 0.006
IPM0827 487299694 17028124 3.49% 469539303 96.36% 434591 0.09% 0.084
IPM0828 495674080 15472269 3.12% 479291366 96.69% 539846 0.11% 0.257
IPM0829 257872145 8337968 3.23% 248888739 96.52% 367106 0.14% 0.043
IPM0830 52238718 1602630 3.07% 50496988 96.67% 86414 0.17% 5.996
IPM0831 50418659 1569256 3.11% 48749241 96.69% 58030 0.12% 9.212
IPM0832 53019251 1596825 3.01% 51296766 96.75% 80243 0.15% 3.524
IPM0833 62256881 1971793 3.17% 60152942 96.62% 85274 0.14% 1.898
IPM0834 16878011 14157443 83.88% 2406262 14.26% 26924 0.16% 14.725
IPM0835 21024466 2507397 11.93% 18458548 87.80% 6010 0.03% 4.519
IPM0836 20431295 2479531 12.14% 17906335 87.64% 6190 0.03% 9.805
IPM0837 12600089 698303 5.54% 11867411 94.19% 7257 0.06% 14.27
IPM0838 4803516 419410 8.73% 4348770 90.53% 2545 0.05% 7.229
IPM0839 12322992 319129 2.59% 11964574 97.09% 8121 0.07% 13.049
IPM0840 10357436 1284482 12.40% 9035195 87.23% 5194 0.05% 0.807
IPM0841 9895503 308278 3.12% 9569011 96.70% 3844 0.04% 0.986
IPM0842 11095736 440858 3.97% 10636410 95.86% 4290 0.04% 7.048
IPM0843 62687436 1692351 2.70% 60915334 97.17% 32240 0.05% 0.234
IPM0844 43269168 1112682 2.57% 42074839 97.24% 23927 0.06% 0.12
IPM0845 61618439 2067065 3.35% 59446731 96.48% 54361 0.09% 0.188
IPM0846 19946502 505495 2.53% 19403119 97.28% 7961 0.04% 0.139
IPM0847 13766300 287727 2.09% 13453084 97.72% 5234 0.04% 0.233
IPM0848 14290972 363880 2.55% 13900381 97.27% 5986 0.04% 0.197
IPM0849 14214873 6127174 43.10% 7769890 54.66% 17782 0.13% 6.656
IPM0850 20608401 559572 2.72% 20022795 97.16% 6695 0.03% 0.257
IPM0851 19319677 560000 2.90% 18740626 97.00% 5862 0.03% 0.224
IPM0852 12455639 315176 2.53% 12106890 97.20% 4126 0.03% 0.157
IPM0853 18306919 527085 2.88% 17740737 96.91% 9150 0.05% 1.212
IPM0854 16221337 522477 3.22% 15665628 96.57% 8055 0.05% 0.214
IPM0855 21137657 4283404 20.26% 16672221 78.87% 20589 0.10% 6.578
IPM0856 22063704 980652 4.44% 21056874 95.44% 10908 0.05% 1.703
IPM0857 20324726 1752364 8.62% 18537771 91.21% 10195 0.05% 2.966
IPM0858 42916606 1187214 2.77% 41668154 97.09% 32262 0.08% 0.07
IPM0859 50069240 3545788 7.08% 46440091 92.75% 27543 0.06% 3.983
IPM0860 30454577 668050 2.19% 29748938 97.68% 14023 0.05% 0.493
IPM0861 21752609 1005150 4.62% 20704878 95.18% 10049 0.05% 1.539
IPM0862 8869254 126835 1.43% 8729065 98.42% 6492 0.07% 0.36
IPM0863 13619910 261754 1.92% 13335003 97.91% 8879 0.07% 0.04
IPM0864 11574071 216112 1.87% 11341552 97.99% 5520 0.05% 0.084
IPM0865 10647826 248229 2.33% 10383391 97.52% 4824 0.05% 0.177
IPM0866 6687209 138236 2.07% 6533061 97.69% 2428 0.04% 0.087
IPM0867 13933453 245334 1.76% 13655152 98.00% 7811 0.06% 0.156
IPM0868 3725277 37399 1.00% 3659738 98.24% 1409 0.04% 0.078
IPM0869 7809393 185361 2.37% 7603645 97.37% 2726 0.03% 0.17
IPM0870 3616290 76017 2.10% 3525802 97.50% 1248 0.03% 0.111
IPM0871 5025825 153013 3.04% 4858187 96.66% 1844 0.04% 0.065
IPM0872 8866570 910183 10.27% 7930074 89.44% 4590 0.05% 0.229
IPM0873 8181686 2128832 26.02% 6016069 73.53% 5810 0.07% 3.201
IPM0874 15168527 415418 2.74% 14708024 96.96% 5063 0.03% 0.046
IPM0875 9240454 154332 1.67% 9048712 97.92% 2780 0.03% 0.04
IPM0876 7069623 75361 1.07% 6963338 98.50% 1784 0.03% 0.004
IPM0877 12469488 255390 2.05% 12185838 97.73% 5484 0.04% 0.081
IPM0878 14071291 305383 2.17% 13720389 97.51% 8432 0.06% 0.296
IPM0879 12598603 1300202 10.32% 11271515 89.47% 4095 0.03% 1.044
IPM0880 14373494 608152 4.23% 13741497 95.60% 4006 0.03% 0.076
IPM0881 17958639 574899 3.20% 17353431 96.63% 10576 0.06% 0.131
IPM0882 13894618 268993 1.94% 13595112 97.84% 4968 0.04% 0.099
IPM0883 5583577 106984 1.92% 5447718 97.57% 1683 0.03% 0.81
IPM0890 37451770 998022 2.66% 36418078 97.24% 18832 0.05% 0.209
IPM0891 31058853 794103 2.56% 30232085 97.34% 14243 0.05% 0.155
IPM0892 16580033 397188 2.40% 16155252 97.44% 11823 0.07% 0.138
IPM0893 16070169 717622 4.47% 15313143 95.29% 6376 0.04% 0.207
IPM0894 16195763 443370 2.74% 15725136 97.09% 9178 0.06% 0.094
IPM0895 27386159 1030445 3.76% 26302107 96.04% 14005 0.05% 0.182
IPM0896 18743065 1191990 6.36% 17519566 93.47% 8297 0.04% 0.294
IPM0897 22476344 601354 2.68% 21840642 97.17% 10989 0.05% 0.05
IPM0898 21477768 571675 2.66% 20875224 97.19% 9674 0.05% 0.079
IPM0899 23432707 1182933 5.05% 22201706 94.75% 10229 0.04% 0.157
IPM0900 16683802 579733 3.47% 16069798 96.32% 7011 0.04% 0.085
IPM0901 17240772 1190723 6.91% 16014873 92.89% 6713 0.04% 0.136
IPM0902 3285 432 13.15% 2844 86.58% 0 0.00% 0.632
IPM0903 2442 391 16.01% 2044 83.70% 0 0.00% 0.104
IPM0904 18414293 2746153 14.91% 15610730 84.78% 8723 0.05% 0.081
IPM0905 19674860 8676628 44.10% 10916860 55.49% 9816 0.05% 0.722
IPM0906 21474264 613609 2.86% 20822712 96.97% 12631 0.06% 0.024
Table S2, Genes with Modules, Related to Figure 5
Module 1 gene list B3GNTL1 COPRS EXD3 HLA-A LINC02210 NDEL1 PMVK RREB1 SPRY2 TTC30B Module 2 gene list
ABCA1 B4GALT1 COQ6 EXO5 HLA-B LINC02649 NDRG1 PNISR RSAD2 SPTY2D1 TTC9 A2M
ABCA3 B4GALT5 CORO1A EXOC8 HLA-C LITAF NDST1 PNKD RSC1A1 SQOR TTLL3 ALAS2
ABCB6 BAALC CORO1C EXOSC5 HLA-DQA1 LMNB1 NDUFA6-DT PNPLA6 RSRC2 SQSTM1 TTLL4 ATP1B1
ABCG1 BACH1 CORO7 EYA3 HLA-E LMO7 NDUFAF5 PNRC1 RSRP1 SRC TUBB2B COL20A1
ABHD2 BACH2 COTL1 F11R HLA-F LMTK2 NDUFAF8 POGLUT3 RTF2 SRD5A3 TUG1 CPED1
ABHD5 BASP1 CPD FADS1 HM13 LOC400499 NDUFS4 POLR2A RTN3 SREBF1 TUT7 EPHA1
ABR BAZ1A CPEB4 FAM111B HMBS LONP1 NEAT1 POLR2I RTN4 SRGN TXNDC5 EPS8
ABTB1 BAZ2A CPPED1 FAM117B HMGA1 LPAR2 NECAB3 POLR3B RTN4IP1 SRRM2 TXNIP ERICH3
ACAA1 BAZ2B CPQ FAM120C HMGN3 LPAR5 NECAP1 POM121 RUBCNL SSH2 TYK2 FCGBP
ACACB BBS12 CR1 FAM126B HNRNPA2B1 LPCAT1 NEDD9 POM121C RXRA SSR2 TYMP GPR34
ACADVL BCAN CREB1 FAM157A HNRNPC LRCH4 NEIL2 PON2 RXYLT1 SSU72 TYROBP HBA1
ACAP2 BCAS4 CREB5 FAM160A2 HNRNPF LRFN4 NEU1 POR RYBP SSX2IP TYW3 HBA2
ACAT1 BCKDHB CREBBP FAM193B HNRNPH2 LRG1 NF1 PORCN RYR1 ST14 UACA HBB
ACBD4 BCKDK CREBRF FAM210A HNRNPK LRMDA NFAM1 POU2F2 S100A11 ST20 UBA1 HBG1
ACIN1 BCL10 CRISPLD2 FAM210B HNRNPM LRP1 NFAT5 PPCDC S100A12 ST3GAL1 UBAP1 HBG2
ACOT2 BCL2A1 CRK FAM214B HNRNPU LRP10 NFE2L2 PPFIA1 S100A6 ST3GAL2 UBC HLA-DQA1
ACP2 BCL3 CROT FAM49B HOMER2 LRP3 NFIA PPIF S100A8 ST8SIA4 UBE2D1 HTRA1
ACSL1 BCL6 CRTC2 FAM53C HOPX LRPAP1 NFIL3 PPIL3 S100A9 STAC3 UBE2D3 IGFBP7
ACSL4 BDH1 CRYBG1 FAM89A HPCAL1 LRRC25 NFIX PPM1F SAFB STAG3 UBE2R2 LPL
ACSL5 BDH2 CSF1 FAM91A1 HPF1 LRRFIP1 NFKB1 PPM1H SAFB2 STAT1 UBE2W LSAMP
ACTB BEST1 CSF2RB FANCE HPSE LRRK2 NFKB2 PPP1CB SAMD4B STAT2 UBE4A RNA5-8SN1
ACTG1 BEX3 CSF3R FANCF HS3ST3B1 LSP1 NFKBIA PPP1R10 SAMD8 STAT3 UBR4 RNA5-8SN2
ACTN1 BHLHE40 CSGALNACT2 FASTKD3 HSD17B11 LST1 NFKBID PPP1R12C SAMD9 STAT5A UBXN2B RNA5-8SN3
ACTN4 BID CSK FBRS HSD17B4 LTA4H NFKBIE PPP1R15A SAMD9L STAT5B UNC119 RNA5-8SN5
ACTR2 BIN1 CSNK1A1 FBXL5 HSF2 LUCAT1 NFKBIZ PPP1R15B SAMSN1 STAT6 UNC13D SEMA5A
ACTR3 BIRC3 CSNK1D FBXO32 HSP90AA1 LXN NFU1 PPP1R18 SAPCD2 STEAP4 UPB1 SIGLEC8
ACVR1B BIRC6 CSNK1G2 FBXO38 HSP90B1 LYN NFXL1 PPP1R3B SARS2 STK10 UPF1 TREM2
ACY1 BIVM CSRNP1 FBXO4 HSPA1A LYPLAL1 NIBAN1 PPP1R3G SASH3 STK35 UPP1
ADAM10 BMP1 CSTB FBXW7 HSPA1B LYST NIBAN2 PPP2R2D SAT1 STK4 USB1
ADAM17 BMS1P1 CTBS FBXW8 HSPA5 LYVE1 NID1 PPP4C SBDSP1 STK40 USF3
ADAM8 BOD1L1 CTDP1 FCAR HSPA6 LYZ NINJ1 PPP4R2 SBF2 STMN3 USP15
ADAMTSL4-AS1 BOLA3 CTDSP1 FCER1G HSPH1 LZTFL1 NIPBL PRADC1 SBNO1 STON2 USP3
ADAR BPGM CTNNBIP1 FCGR1B HTR7 M6PR NLRC4 PRAM1 SBNO2 STRADB USP32
ADCY3 BPHL CTPS2 FCGR2A ICAM1 MACROH2A1 NLRC5 PRDM11 SCAF1 STX11 USP34
ADCY6 BRAF CTSA FCGR2B ICAM3 MAEA NMI PRDM2 SCAF11 STX3 USP4
ADGRB1 BRD2 CTSB FCGR3A ID3 MAFB NMT2 PREX1 SCAMP5 STX4 USP54
ADGRE1 BRD4 CTSC FCGR3B IDS MAFF NOD2 PRIM1 SCARF1 STX6 USP8
ADGRE2 BRI3 CTSD FCN1 IDUA MAFG NOP10 PRIMPOL SCARNA10 STXBP2 USP9X
ADGRE3 BRIP1 CTSF FCRL1 IER2 MAFK NOTCH1 PRKAR1A SCARNA13 STXBP4 VASP
ADGRE4P BRPF3 CTSK FDXR IER3 MAGEF1 NOTCH2 PRKAR1B SCIN SULF2 VAV1
ADGRE5 BRWD3 CTSL FECH IER5 MAGEH1 NOTCH2NLA PRKCB SCN3A SUN2 VCAN
ADGRG3 BST1 CTSS FERMT3 IFI16 MALAT1 NPC1 PRKCD SCN9A SUPT3H VCPIP1
ADGRL1 BTBD19 CTSZ FFAR2 IFI30 MAML1 NPEPPS PRKCQ-AS1 SDCBP SUPT5H VDR
ADM BTG2 CUX1 FGD3 IFIH1 MAML2 NPIPB3 PRKCZ SDF4 SUPT6H VEGFA
ADORA2A BTN2A1 CUX2 FGFR1 IFIT1 MAN1A1 NPIPB5 PRKD2 SEC14L1 SUSD6 VHL
ADPGK BTN2A2 CWC25 FGFRL1 IFIT2 MAP1B NPLOC4 PRLR SEC16A SVIL VIM
AFAP1 BTN3A1 CXCL1 FGR IFIT3 MAP1LC3B NR1H3 PRMT9 SEC22B SVIP VMP1
AFF1 BYSL CXCL16 FILIP1L IFITM1 MAP1S NR3C1 PROK2 SEC24A SYK VNN1
AFF4 BZW1 CXCL2 FKBP14 IFITM2 MAP2 NR4A2 PROS1 SEC61A1 SYNPO VNN2
AFMID C10orf88 CXCL5 FKBP15 IFITM3 MAP2K3 NR4A3 PRR13 SECTM1 SZT2 VNN3
AFTPH C11orf95 CXCL8 FKBP9 IFNAR1 MAP3K10 NRBF2 PRR14L SEL1L TAB2 VOPP1
AGAP3 C12orf29 CXCR1 FLCN IFNGR1 MAP3K11 NRBP1 PRRC2A SELL TACO1 VPS13B
AGBL5 C15orf39 CXCR2 FLII IFNGR2 MAP3K2 NRDC PRRC2C SEMA4A TAF7 VPS13D
AGO2 C15orf48 CXCR4 FLNA IFNLR1 MAP3K8 NRXN1 PRUNE2 SEMA4B TAF9B VPS18
AGO4 C16orf72 CYB5R4 FLOT1 IGF2R MAP4K4 NSDHL PRXL2A SEMA4D TAGAP VPS37C
AGTPBP1 C17orf75 CYBA FLOT2 IGFBP5 MAP7D1 NSMAF PRXL2B SEMA6B TAGLN2 VPS4B
AGTRAP C1orf198 CYBB FLT3LG IGIP MAPK13 NT5C2 PSAP SEPTIN3 TALDO1 VPS8
AHCTF1 C1orf50 CYBC1 FLYWCH2 IGLL5 MAPK14 NT5DC1 PSAT1 SEPTIN7P2 TANC2 VPS9D1
AHNAK C1orf54 CYFIP2 FMNL1 IGSF6 MAPK6 NUCB1 PSD SERF2 TANK VSIR
AHR C1RL CYP27A1 FN1 IKBKB MAPK8IP1 NUDT12 PSEN1 SERINC1 TAOK1 WAC
AIF1 C2CD3 CYP2U1 FNBP1L IL10RB MAPKAPK2 NUDT15 PSMG1 SERP1 TAP1 WARS1
AIFM3 C3AR1 CYSTM1 FNDC3B IL11RA MARCHF6 NUFIP2 PSTPIP1 SERPINA1 TAP2 WAS
AK1 C4orf3 CYTH4 FNIP1 IL17RA MARCHF7 NUMB PSTPIP2 SERPINB1 TAPBP WASHC2A
AK4 C5AR1 CYTIP FNIP2 IL18BP MARCHF9 NUP35 PTAFR SERPINB9 TATDN1 WASHC2C
AK6 C6orf62 DAAM1 FOS IL18RAP MARCKS NUP58 PTBP3 SERPING1 TBC1D14 WASHC4
AKAP10 C6orf89 DANCR FOSL2 IL1A MARCO NUP98 PTEN SETD5 TBC1D2 WBP2
AKAP13 C9orf72 DAPK1 FOXO3 IL1B MARF1 NXF1 PTGDR SETD6 TBC1D22A WDFY3
AKAP17A C9orf85 DAPP1 FOXRED2 IL1R1 MARK3 NYNRIN PTGER4 SETX TBC1D9B WDR1
AKAP6 CA5BP1 DARS1 FPR1 IL1R2 MARS2 OAS3 PTGFRN SF1 TBK1 WDR26
AKAP7 CABLES1 DAZAP2 FPR2 IL1RAP MAST3 OAZ2 PTGR1 SF3A1 TBL1X WDR53
AKIRIN2 CACNB1 DBNL FRAT2 IL1RN MAU2 OCEL1 PTGS2 SF3B1 TBL1XR1 WFS1
AKNA CADM1 DCANP1 FRMD3 IL2RG MBD6 OCIAD2 PTK2B SF3B2 TCAF2 WIPF1
ALDH4A1 CAMKK1 DCP2 FTH1 IL4I1 MBLAC2 OCRL PTK7 SFXN2 TCEAL9 WIPF2
ALDH5A1 CAMKK2 DCUN1D3 FUOM IL4R MBOAT7 OGA PTP4A2 SFXN4 TCIRG1 WNK1
ALDH6A1 CAMTA2 DDIT3 FURIN IL6R MBP OGFR PTPDC1 SGK1 TCTN1 WSB1
ALDOA CANT1 DDIT4 FUS IL6ST MBTPS2 OLFML2B PTPN1 SGSH TDP2 WTAP
ALDOC CANX DDX17 FUT10 ILRUN MCEMP1 OLFML3 PTPN12 SGTB TECPR2 WWC3
ALKBH4 CAP1 DDX39B FYB1 IMPDH1 MCF2L OPHN1 PTPN2 SH2D3C TEF WWOX
ALKBH7 CAPS DDX3X FZD1 INO80B MCF2L2 OPLAH PTPN23 SH3BGRL3 TESC WWP2
ALKBH8 CAPZA1 DDX58 G0S2 INPP5D MCL1 ORAI2 PTPN6 SH3BP2 TET2 XBP1
ALOX5 CAPZA2 DDX6 GAB2 IP6K1 MCOLN1 ORM1 PTPRC SH3BP4 TET3 XIAP
ALOX5AP CARD16 DDX60L GABARAP IPMK MCTP1 OS9 PTPRE SH3BP5 TFB1M XPA
ALPK1 CARD8 DEDD2 GABARAPL2 IQGAP1 MCTP2 OSBP PTPRJ SH3D21 TFE3 XPO6
ALPL CARMIL1 DENND2B GADD45B IQSEC1 MDM2 OSBPL2 PTRH1 SH3PXD2B TFEC XRN1
ALS2CL CASC3 DENND3 GAK IQSEC2 MDM4 OSBPL8 PTRHD1 SHC3 TFRC YEATS4
AMDHD2 CASP1 DENND4B GALNS IRAK1 ME1 OSER1 PTS SHISA5 TG YIPF3
AMIGO2 CASP4 DENND5A GAPDH IRAK2 MECP2 OSM PTTG1IP SHKBP1 TGFB1 YPEL3
AMOTL1 CASP5 DEXI GAPT IRAK3 MED13L OXSR1 PXN SHMT1 TGM2 YTHDF3
AMPD2 CASS4 DGAT2 GBE1 IRF1 MED15 P2RX1 PYCR1 SHOC2 TGOLN2 YWHAZ
AMPD3 CAST DHRS4 GBP1 IRF2 MED28 P2RX4 QKI SIAE THBD ZBED6
ANAPC10 CBL DHRS4-AS1 GBP2 IRF2BP2 MEFV P2RY13 QPCT SIGLEC10 THBS1 ZBTB17
ANK1 CCDC112 DHX34 GBP4 IRF7 MEGF9 P2RY2 QSOX1 SIGLEC11 THEM4 ZBTB42
ANK2 CCDC138 DIAPH1 GBP5 IRF9 MELTF P4HA1 R3HDM4 SIGLEC14 THEM6 ZBTB7B
ANKAR CCDC141 DICER1 GCA IRS1 METTL2A P4HB RAB10 SIGLEC16 THEMIS2 ZC3H11A
ANKDD1A CCDC15 DIP2B GCC1 IRS2 METTL5 PACRGL RAB11FIP1 SIGLEC5 THOC3 ZC3H12A
ANKH CCDC57 DIP2C GCH1 ISG15 MFSD14A PACSIN2 RAB1A SIGLEC9 THUMPD2 ZC3H18
ANKHD1 CCDC71L DIPK1A GDF11 ISG20 MFSD2A PAG1 RAB20 SIK3 TICAM1 ZCCHC2
ANKRD11 CCDC86 DISP1 GDI1 ISOC1 MGA PAK1 RAB21 SIPA1 TIFA ZCCHC24
ANKRD12 CCDC88B DLG5 GGA1 IST1 MGAM PAK2 RAB24 SIPA1L1 TIGD2 ZDHHC14
ANKRD13A CCDC93 DMAC1 GGA3 ITCH MGAT1 PAPOLA RAB3D SIPA1L2 TIGD5 ZDHHC18
ANKRD22 CCL18 DMXL2 GGT7 ITGA3 MGLL PAQR7 RAB4A SIRPA TIMM21 ZDHHC5
ANKRD33B CCL2 DNAAF2 GGTA1P ITGA5 MICALL2 PARP10 RAB5A SIRPB1 TIMM9 ZEB2
ANKRD46 CCL3 DNAJB1 GIGYF1 ITGAM MIDN PARP14 RAB5C SIRPB2 TIMP1 ZFAND3
ANKRD9 CCL3L1 DNAJB6 GIGYF2 ITGAX MIER1 PARP2 RAB7A SIRT7 TKT ZFAND5
ANKS6 CCL4 DNAJC19 GK ITGB2 MIF PARP6 RAB7B SKAP1 TLCD4 ZFC3H1
ANKZF1 CCL4L2 DNAJC3 GLG1 ITIH4 MIPEP PARP9 RAB8B SKAP2 TLE3 ZFP30
ANOS1 CCND1 DNAJC5 GLT1D1 ITM2B MIR210HG PATL1 RABGEF1 SKIL TLE4 ZFP36
ANP32A CCNG2 DNAL1 GLUL ITPR2 MKNK1 PAXBP1-AS1 RAC2 SLA TLN1 ZFP36L1
ANPEP CCNK DNLZ GMFG ITPRIP MKNK2 PBX2 RAD21 SLAIN1 TLN2 ZFYVE16
ANTXR1 CCNL1 DNM2 GMIP ITSN2 MLLT6 PBX3 RAD51C SLAMF7 TLR1 ZFYVE26
ANTXR2 CCNL2 DNM3 GNA15 IVNS1ABP MMAA PCBD1 RAF1 SLAMF8 TLR2 ZHX2
ANXA3 CCR1 DOCK2 GNAI2 JAK1 MME PCBP1 RALB SLC11A1 TLR4 ZIK1
ANXA5 CCRL2 DOCK4 GNAI3 JAK2 MMP12 PCBP1-AS1 RALGAPA2 SLC11A2 TLR6 ZKSCAN2
AP1G1 CD14 DOCK5 GNB1 JAK3 MMP14 PCBP2 RALGDS SLC12A6 TLR8 ZMIZ1
AP3D1 CD163 DOCK8 GNB2 JAML MMP19 PCDH12 RANBP2 SLC12A9 TM7SF2 ZMIZ2
AP5B1 CD177 DOK3 GNG2 JAZF1 MMP2 PCF11 RANGRF SLC15A3 TM9SF4 ZMYND19
AP5Z1 CD22 DOT1L GNG7 JCHAIN MMP25 PCGF6 RAP1B SLC16A1-AS1 TMBIM1 ZNF10
APBA1 CD24 DPH5 GNLY JMJD1C MMP9 PCNX1 RAP2C SLC16A3 TMBIM4 ZNF117
APBA3 CD274 DPH6 GNPDA1 JMJD6 MNDA PCNX3 RAPGEF1 SLC16A6 TMBIM6 ZNF132
APBB1IP CD276 DPY30 GNPDA2 JUN MNT PDGFC RARA SLC19A1 TMCC1 ZNF16
APBB3 CD300A DPYD GNS JUNB MOB1A PDIA3 RARG SLC19A2 TMCC2 ZNF160
APLF CD300E DRAM1 GOLGA2P7 KANK2 MOB3A PDK1 RASAL2 SLC20A1 TMCC3 ZNF207
APLP2 CD36 DSC2 GON7 KAT5 MOB3C PDLIM7 RASGRP4 SLC24A1 TMEM127 ZNF217
APOBEC3A CD37 DSE GORAB KAT6A MON1B PDXK RASSF2 SLC25A13 TMEM140 ZNF23
APOBR CD44 DTD2 GOT1 KATNBL1 MON2 PDZD11 RASSF3 SLC25A23 TMEM154 ZNF24
APOC2 CD48 DTWD2 GPAT4 KBTBD6 MOSPD1 PECAM1 RASSF4 SLC25A37 TMEM159 ZNF267
APOL6 CD53 DTX2 GPATCH2L KCNAB2 MPC1 PELI1 RASSF5 SLC25A38 TMEM165 ZNF274
AQP9 CD55 DTX3 GPBP1 KCNJ15 MPEG1 PER1 RBCK1 SLC25A43 TMEM176B ZNF281
ARAP1 CD58 DTX3L GPBP1L1 KCNJ2 MPP6 PEX10 RBFA SLC26A11 TMEM184B ZNF286A
ARAP3 CD63 DUSP1 GPCPD1 KCNK13 MR1 PEX12 RBM23 SLC2A1 TMEM201 ZNF292
AREL1 CD68 DUSP16 GPHN KCTD17 MRPL40 PEX3 RBM25 SLC2A3 TMEM242 ZNF316
ARF1 CD82 DUSP2 GPI KCTD3 MRPL58 PFKFB2 RBM33 SLC2A6 TMEM254 ZNF32
ARFIP1 CD93 DUSP3 GPM6B KDM2A MRPS17 PFKFB3 RBM39 SLC35D2 TMEM259 ZNF324B
ARHGAP25 CDC42 DUSP6 GPN3 KDM3A MRPS28 PFKFB4 RBM47 SLC35E1 TMEM273 ZNF329
ARHGAP26 CDC42EP3 DYRK1A GPR108 KDM3B MRPS31P5 PFKL RBM5 SLC35E3 TMEM42 ZNF331
ARHGAP27 CDC42SE1 DYSF GPR65 KDM4B MRPS33 PFN1 RBPJ SLC38A10 TMEM64 ZNF333
ARHGAP30 CDC42SE2 E2F3 GPR84 KDM5C MRVI1 PGAM1 RC3H1 SLC39A14 TMEM71 ZNF35
ARHGAP33 CDK18 EAF1 GPRASP1 KDM6A MS4A4E PGAP1 RDH10 SLC39A8 TMEM86B ZNF354C
ARHGAP45 CDK5R1 EBAG9 GPSM1 KDM6B MSANTD2 PGAP6 REC8 SLC3A2 TMF1 ZNF358
ARHGAP9 CDKN1A ECE1 GPSM2 KDM7A MSL1 PGBD2 RECK SLC43A1 TMOD3 ZNF382
ARHGDIA CDKN2AIPNL ECI1 GPSM3 KDM8 MSMO1 PGBD4 REL SLC43A2 TMSB4X ZNF395
ARHGDIB CDV3 ECI2 GRAMD1A KHNYN MSN PGK1 RELA SLC43A3 TMTC4 ZNF438
ARHGEF1 CEACAM1 EDEM1 GRASP KIAA0040 MSRB1 PGM2L1 RELB SLC45A4 TNFAIP2 ZNF462
ARHGEF2 CEACAM3 EEF1AKMT3 GRB2 KIAA0232 MTF1 PGS1 RELT SLC5A3 TNFAIP3 ZNF470
ARHGEF9 CEBPB EEF1E1 GRINA KIAA0513 MTFR1 PHACTR1 RERE SLC6A6 TNFAIP6 ZNF48
ARID3A CELF1 EEF2KMT GRK2 KIF1A MTHFS PHC2 RESF1 SLC7A7 TNFRSF10C ZNF527
ARID3B CENPL EFCAB13 GRK6 KIF24 MTMR11 PHF12 RFFL SLC9A7P1 TNFRSF10D ZNF542P
ARID4B CEP170 EFHD2 GRN KIF5C MTMR3 PHF20L1 RFK SLC9A8 TNFRSF14 ZNF546
ARL4A CEP170B EGLN1 GSAP KIFC3 MTMR4 PHF21A RGL2 SLC9B2 TNFRSF1A ZNF550
ARMCX2 CEP57L1 EGLN2 GSDMD KLF10 MTSS2 PI3 RGPD2 SLCO4A1 TNFRSF1B ZNF568
ARMH1 CEP76 EGR3 GSK3A KLF6 MTURN PIAS1 RGS19 SLK TNFRSF8 ZNF570
ARNT2 CERK EHBP1L1 GSPT2 KLHL2 MVP PICALM RHBDD2 SLPI TNFSF10 ZNF573
ARPC1B CERT1 EHD1 GSTCD KLHL20 MX1 PIGU RHBDF2 SLU7 TNFSF14 ZNF593
ARPC2 CFAP298 EIF1 GSTM2 KLHL21 MX2 PIGW RHOA SLX1B-SULT1A4 TNIP1 ZNF608
ARPC3 CFL1 EIF3A GTF2H4 KMT2B MXD1 PIK3AP1 RHOBTB2 SMAD6 TNIP2 ZNF618
ARPC4 CFL2 EIF4G1 GTF2H5 KMT2C MYADM PIK3CB RHOG SMAP2 TNR ZNF626
ARPC5 CFLAR EIF4H GTPBP1 KMT2D MYD88 PIK3CD RHOQ SMCHD1 TNRC18 ZNF641
ARRB2 CFP EIF5 GTPBP2 KMT2E MYEF2 PIK3R3 RICTOR SMCR8 TNS1 ZNF646
ARRDC2 CHCHD10 ELAC1 GTPBP8 KMT5C MYH9 PIK3R5 RILPL2 SMG1 TNS3 ZNF704
ARRDC3 CHD2 ELF1 GUK1 KPNA4 MYL12A PILRA RIPOR1 SMG1P1 TOM1 ZNF710
ARSG CHEK2 ELF2 GUSBP1 KPNB1 MYL6 PIM1 RIPOR2 SMG1P3 TOR1AIP2 ZNF710-AS1
ARV1 CHFR ELF4 GUSBP1 KRAS MYLIP PIM2 RIT1 SMG7 TOX4 ZNF718
ASAH1 CHI3L1 ELL GUSBP3 KRBA2 MYO1B PIM3 RLF SMIM25 TP53BP1 ZNF738
ASF1A CHIT1 ELMSAN1 H2AC19 KREMEN1 MYO1F PIN4 RLIM SMYD3 TP53I3 ZNF74
ASGR1 CHMP1A EMD H2BC18 KRT23 MYO1G PISD RMND5A SNAP23 TPD52L2 ZNF773
ATF5 CHMP2A EMILIN2 H3-3A LAMB3 MYO5B PITPNA RMRP SNCA TPI1 ZNF777
ATG10 CHMP3 EML2 H3-3B LAMP1 MYO9B PJA2 RN7SK SNN TPM2 ZNF792
ATG16L2 CHMP4B EML4 H3C6 LAMP2 MZB1 PKD1P6-NPIPP1 RN7SL1 SNORA48 TPM3 ZNF799
ATG2A CHN2 ENAH H4C1 LAPTM5 N4BP1 PKM RN7SL2 SNORA73A TPM4 ZNF804A
ATG3 CHRNB1 ENDOD1 HAAO LARP4B N4BP2L2 PKN1 RNASEK SNORA73B TPP1 ZNF813
ATG7 CHST11 ENO1 HADH LASP1 N6AMT1 PLA2G4A RNF13 SNORD17 TPRA1 ZNF846
ATIC CHST14 ENTPD4 HAL LAT2 NAA20 PLAG1 RNF130 SNORD3A TRAF1 ZNFX1
ATP11A CHST15 EP300 HBP1 LBR NAB1 PLAGL2 RNF144A SNTA1 TRAF3 ZSCAN12
ATP11B CHSY1 EPB41L1 HCAR2 LCP1 NABP1 PLAU RNF144B SNX10 TRAFD1 ZSCAN2
ATP13A3 CIC EPB41L2 HCAR3 LCP2 NADK PLAUR RNF145 SNX18 TRAK1 ZSCAN5A
ATP1A1 CKAP4 EPB41L5 HCK LDHA NAGK PLCG2 RNF149 SNX20 TRANK1 ZSWIM4
ATP2A3 CKLF EPG5 HCLS1 LENG8 NAIP PLCL1 RNF157 SNX21 TREM1 ZSWIM8
ATP2B1 CLCN7 EPHB3 HCP5 LEP NAMPT PLEC RNF19B SNX24 TREML2 ZXDA
ATP6AP1 CLEC4E EPHX1 HDAC11 LEPROT NAPA PLEK RNF213 SNX27 TRIAP1 ZYX
ATP6V0B CLEC7A EPS15L1 HDAC4 LGALS3 NAPEPLD PLEKHA2 RNF24 SOCS3 TRIB1 ZZEF1
ATP6V0C CLIC1 EPSTI1 HDAC7 LGALS8 NARF PLEKHB1 RNF40 SOD2 TRIM25
ATP6V0D1 CLIC4 ERBIN HDDC3 LIAS NARS2 PLEKHB2 RNF8 SON TRIM33
ATP6V0E2 CLK1 ERCC8 HDGFL3 LILRA1 NBEA PLEKHG3 RNMT SORBS1 TRIM38
ATP6V1A CLK3 ERF HECA LILRA2 NBEAL2 PLEKHM1 RNU1-1 SORL1 TRIM56
ATP6V1B2 CLN3 ERI3 HELB LILRA5 NBL1 PLEKHM2 RNU1-2 SOWAHC TRIP12
ATP6V1C1 CLUAP1 ERN1 HELZ2 LILRA6 NBN PLEKHO1 RNU1-3 SOX12 TRPC4AP
ATP6V1E1 CMAS ERO1A HEXIM1 LILRB1 NBPF14 PLEKHO2 RNU1-4 SP1 TRPM2
ATP6V1E2 CMIP ERV3-1 HGF LILRB2 NBPF19 PLIN2 RNU4-1 SP100 TRPM7
ATP6V1G1 CMSS1 ESCO1 HGS LILRB3 NBR1 PLIN4 RNU4-2 SP110 TRPV1
ATXN1 CMTM6 ESR1 HHAT LILRB4 NCAM1 PLIN5 RNVU1-18 SP3 TRUB1
ATXN7 CNBP ETAA1 HIF1A LIMK2 NCF1 PLK3 RNVU1-29 SPAG9 TSC22D3
AVL9 CNN2 ETF1 HILPDA LINC00339 NCF1B PLP1 ROCK1 SPATC1 TSC22D4
AVPI1 CNN3 ETFRF1 HINT2 LINC00476 NCF1C PLP2 RP2 SPECC1L-ADORA2A TSEN2
AXL CNOT1 ETS2 HIP1 LINC00528 NCF2 PLPP3 RPA3 SPEN TSEN34
AZIN1 CNOT3 ETV6 HIPK3 LINC00865 NCF4 PLPPR2 RPP25 SPG11 TSNARE1
B2M COL18A1 EVI2A HIVEP1 LINC00893 NCOA1 PLSCR1 RPPH1 SPHK1 TSPAN14
B3GLCT COL1A1 EVI2B HIVEP2 LINC00937 NCOR2 PLTP RPS6KA1 SPI1 TSPAN5
B3GNT5 COL8A2 EWSR1 HK2 LINC01184 NCS1 PLXNC1 RPUSD2 SPOPL TTC28
B3GNT8 COMMD3-BMI1 EXD2 HK3 LINC01270 NCSTN PMEPA1 RRAGC SPPL2A TTC30A
Table S3, Genes from Proteogenomic Integration, Related to Figure 7
Gene_Name Gene_Mean Gene_std Sample_Type Assay
A2M 39.2 11.73502423 NPIH RNA
A2M 135.56 55.5019911 NonPaeni_PIH RNA
A2M 97.947368 26.94361 Paeni_PIH RNA
ACTN1 1.2285714 0.41228306 NPIH RNA
ACTN1 13.12 5.2187001 NonPaeni_PIH RNA
ACTN1 175.842105 55.506921 Paeni_PIH RNA
ANPEP 0.3428571 0.14333254 NPIH RNA
ANPEP 6.88 2.7985271 NonPaeni_PIH RNA
ANPEP 216.921053 77.077825 Paeni_PIH RNA
APLP2 9.8 2.73884462 NPIH RNA
APLP2 61.72 25.4472921 NonPaeni_PIH RNA
APLP2 672.026316 211.962453 Paeni_PIH RNA
B4GALT1 1.5714286 0.42962833 NPIH RNA
B4GALT1 11.84 4.6847313 NonPaeni_PIH RNA
B4GALT1 140.236842 40.097342 Paeni_PIH RNA
CAP1 7.6 2.19494368 NPIH RNA
CAP1 71.72 29.337323 NonPaeni_PIH RNA
CAP1 477.342105 133.249663 Paeni_PIH RNA
CD14 14.6571429 4.56295345 NPIH RNA
CD14 199.96 76.7045376 NonPaeni_PIH RNA
CD14 1192.842105 372.150024 Paeni_PIH RNA
CFB 0.1714286 0.1227057 NPIH RNA
CFB 0.8 0.2882307 NonPaeni_PIH RNA
CFB 4.157895 1.329377 Paeni_PIH RNA
CHI3L1 0.4571429 0.15088552 NPIH RNA
CHI3L1 3.24 1.2785569 NonPaeni_PIH RNA
CHI3L1 327.763158 116.682184 Paeni_PIH RNA
ENO1 12.9428571 4.1950354 NPIH RNA
ENO1 137.36 54.2521146 NonPaeni_PIH RNA
ENO1 1457.210526 443.381282 Paeni_PIH RNA
FLNA 9.8285714 2.77330979 NPIH RNA
FLNA 164.12 65.5032899 NonPaeni_PIH RNA
FLNA 3886.131579 1720.563964 Paeni_PIH RNA
GAPDH 26.0857143 8.6329354 NPIH RNA
GAPDH 235.04 86.4910752 NonPaeni_PIH RNA
GAPDH 2387.684211 733.492259 Paeni_PIH RNA
HK3 0.8571429 0.36545874 NPIH RNA
HK3 14.08 5.3380838 NonPaeni_PIH RNA
HK3 102.421053 30.000464 Paeni_PIH RNA
HSPA1A 4.7428571 2.74825857 NPIH RNA
HSPA1A 24.08 9.0769226 NonPaeni_PIH RNA
HSPA1A 979.842105 533.003675 Paeni_PIH RNA
ITIH4 0.2285714 0.15979011 NPIH RNA
ITIH4 1.96 0.8457677 NonPaeni_PIH RNA
ITIH4 5.263158 1.918615 Paeni_PIH RNA
LCP1 11.3714286 3.31425151 NPIH RNA
LCP1 179.56 73.4673361 NonPaeni_PIH RNA
LCP1 2150.421053 590.964767 Paeni_PIH RNA
LRG1 0.1714286 0.08438117 NPIH RNA
LRG1 1.88 0.86881 NonPaeni_PIH RNA
LRG1 407.315789 141.803951 Paeni_PIH RNA
LTA4H 1.8 0.68405885 NPIH RNA
LTA4H 32.32 14.0998331 NonPaeni_PIH RNA
LTA4H 166.078947 37.400004 Paeni_PIH RNA
MMP9 0.3714286 0.16468206 NPIH RNA
MMP9 34.32 16.2950412 NonPaeni_PIH RNA
MMP9 312.447368 107.362986 Paeni_PIH RNA
MSN 9.2571429 2.67627521 NPIH RNA
MSN 127.48 49.7424481 NonPaeni_PIH RNA
MSN 835.184211 233.577103 Paeni_PIH RNA
MYH9 9.4 2.6473107 NPIH RNA
MYH9 140.76 52.0221929 NonPaeni_PIH RNA
MYH9 1286.421053 371.399901 Paeni_PIH RNA
PFN1 5.3714286 1.62083934 NPIH RNA
PFN1 100.96 40.9351262 NonPaeni_PIH RNA
PFN1 538.342105 149.108671 Paeni_PIH RNA
PGAM1 4.3142857 2.89080958 NPIH RNA
PGAM1 37.96 15.602414 NonPaeni_PIH RNA
PGAM1 298.578947 93.172454 Paeni_PIH RNA
PGK1 6.0285714 2.07956257 NPIH RNA
PGK1 71.84 30.6036539 NonPaeni_PIH RNA
PGK1 968 293.330977 Paeni_PIH RNA
PKM 14.6285714 5.22950811 NPIH RNA
PKM 132.24 50.8984594 NonPaeni_PIH RNA
PKM 1279.105263 386.18805 Paeni_PIH RNA
PTPRC 8.6857143 3.12307628 NPIH RNA
PTPRC 145 60.2966513 NonPaeni_PIH RNA
PTPRC 1207.605263 335.684923 Paeni_PIH RNA
S100A12 0.1142857 0.06632566 NPIH RNA
S100A12 1.28 0.6691441 NonPaeni_PIH RNA
S100A12 83.973684 27.020123 Paeni_PIH RNA
SDCBP 4.3142857 1.67605519 NPIH RNA
SDCBP 28.52 12.2459563 NonPaeni_PIH RNA
SDCBP 458.026316 135.968171 Paeni_PIH RNA
SERPINB1 1.5142857 0.70189249 NPIH RNA
SERPINB1 15.08 6.6992353 NonPaeni_PIH RNA
SERPINB1 220.473684 73.837009 Paeni_PIH RNA
SIGLEC14 0.3714286 0.18723432 NPIH RNA
SIGLEC14 5.4 2.5660505 NonPaeni_PIH RNA
SIGLEC14 174.684211 55.188807 Paeni_PIH RNA
SOD2 8.6285714 2.73689829 NPIH RNA
SOD2 95.16 40.5393514 NonPaeni_PIH RNA
SOD2 7109.078947 2415.092354 Paeni_PIH RNA
TAGLN2 1.3714286 0.47490302 NPIH RNA
TAGLN2 17.52 6.7153372 NonPaeni_PIH RNA
TAGLN2 178.526316 53.84761 Paeni_PIH RNA
TALDO1 2 0.63245553 NPIH RNA
TALDO1 16.04 6.4844145 NonPaeni_PIH RNA
TALDO1 158.210526 50.789744 Paeni_PIH RNA
VIM 15.8857143 6.94602449 NPIH RNA
VIM 150.12 58.0973274 NonPaeni_PIH RNA
VIM 880.473684 226.804177 Paeni_PIH RNA
YWHAZ 5.6285714 2.23290178 NPIH RNA
YWHAZ 47.32 19.0210992 NonPaeni_PIH RNA
YWHAZ 344.947368 89.984254 Paeni_PIH RNA
A2M 133221.7 9061.293 NPIH Proteomics
A2M 198472.13 15890.586 NonPaeni_PIH Proteomics
A2M 274404.45 27597.465 Paeni_PIH Proteomics
ACTN1 116714.06 9776.423 NPIH Proteomics
ACTN1 119576.72 9089.844 NonPaeni_PIH Proteomics
ACTN1 297445.89 53791.338 Paeni_PIH Proteomics
ANPEP 108576.41 9985.235 NPIH Proteomics
ANPEP 173373.44 17886.847 NonPaeni_PIH Proteomics
ANPEP 216110.82 27340.908 Paeni_PIH Proteomics
APLP2 547840.41 62433.879 NPIH Proteomics
APLP2 328137.7 37983.756 NonPaeni_PIH Proteomics
APLP2 198439.28 24707.301 Paeni_PIH Proteomics
B4GALT1 162247.44 19432.395 NPIH Proteomics
B4GALT1 169430.82 20373.678 NonPaeni_PIH Proteomics
B4GALT1 247502.43 35288.886 Paeni_PIH Proteomics
CAP1 60769.19 6210.648 NPIH Proteomics
CAP1 94136.8 9107.84 NonPaeni_PIH Proteomics
CAP1 296594.36 51942.821 Paeni_PIH Proteomics
CD14 269025.58 30322.495 NPIH Proteomics
CD14 306931.74 26472.734 NonPaeni_PIH Proteomics
CD14 278283.01 33204.389 Paeni_PIH Proteomics
CFB 159222.5 19766.775 NPIH Proteomics
CFB 190851.87 15216.808 NonPaeni_PIH Proteomics
CFB 268398.88 26505.674 Paeni_PIH Proteomics
CHI3L1 321831.41 29053.86 NPIH Proteomics
CHI3L1 434327.09 38137.66 NonPaeni_PIH Proteomics
CHI3L1 424837.82 58773.803 Paeni_PIH Proteomics
ENO1 159438.94 14402.893 NPIH Proteomics
ENO1 196381.01 14636.721 NonPaeni_PIH Proteomics
ENO1 411495.75 55166.856 Paeni_PIH Proteomics
FLNA 165793.31 12503.779 NPIH Proteomics
FLNA 196536.38 14890.969 NonPaeni_PIH Proteomics
FLNA 378300.76 40310.06 Paeni_PIH Proteomics
GAPDH 185309.05 17179.248 NPIH Proteomics
GAPDH 212531.47 20277.813 NonPaeni_PIH Proteomics
GAPDH 443295.9 54278.46 Paeni_PIH Proteomics
HK3 218889.04 22577.89 NPIH Proteomics
HK3 231991.67 26295.58 NonPaeni_PIH Proteomics
HK3 402744.42 65914.391 Paeni_PIH Proteomics
HSPA1A 94243.84 9161.338 NPIH Proteomics
HSPA1A 149336.59 14528.191 NonPaeni_PIH Proteomics
HSPA1A 268265.79 33231.181 Paeni_PIH Proteomics
ITIH4 117579.96 11077.351 NPIH Proteomics
ITIH4 151069.07 12051.139 NonPaeni_PIH Proteomics
ITIH4 199949.48 20480.571 Paeni_PIH Proteomics
LCP1 113417.43 9116.376 NPIH Proteomics
LCP1 195344.4 16039.965 NonPaeni_PIH Proteomics
LCP1 340143.61 43948.485 Paeni_PIH Proteomics
LRG1 108031.17 10929.886 NPIH Proteomics
LRG1 206250.39 22096.464 NonPaeni_PIH Proteomics
LRG1 251746.12 32363.663 Paeni_PIH Proteomics
LTA4H 199245.98 22214.737 NPIH Proteomics
LTA4H 274854.73 21338.75 NonPaeni_PIH Proteomics
LTA4H 414409.87 73708.092 Paeni_PIH Proteomics
MMP9 135606.2 21383.917 NPIH Proteomics
MMP9 172651.95 18211.817 NonPaeni_PIH Proteomics
MMP9 354630.68 52463.93 Paeni_PIH Proteomics
MSN 153328.27 14199.509 NPIH Proteomics
MSN 181385.28 15701.558 NonPaeni_PIH Proteomics
MSN 399781.27 43917.617 Paeni_PIH Proteomics
MYH9 142872.64 12546.343 NPIH Proteomics
MYH9 207808.86 21902.471 NonPaeni_PIH Proteomics
MYH9 379414.18 40316.424 Paeni_PIH Proteomics
PFN1 235567.9 21701.309 NPIH Proteomics
PFN1 280671.85 24642.05 NonPaeni_PIH Proteomics
PFN1 478063.72 65158.86 Paeni_PIH Proteomics
PGAM1 175566.46 28071.23 NPIH Proteomics
PGAM1 167330.31 20852.254 NonPaeni_PIH Proteomics
PGAM1 246561.2 31372.817 Paeni_PIH Proteomics
PGK1 207332.41 16847.118 NPIH Proteomics
PGK1 223880.57 17165.741 NonPaeni_PIH Proteomics
PGK1 358956.96 49762.833 Paeni_PIH Proteomics
PKM 261737.79 17946.082 NPIH Proteomics
PKM 266826.01 19378.661 NonPaeni_PIH Proteomics
PKM 428380.3 43798.24 Paeni_PIH Proteomics
PTPRC 808464.82 76515.077 NPIH Proteomics
PTPRC 831798.58 91176.168 NonPaeni_PIH Proteomics
PTPRC 1128370.95 228452.191 Paeni_PIH Proteomics
S100A12 109727.46 21462.527 NPIH Proteomics
S100A12 117201.9 11805.296 NonPaeni_PIH Proteomics
S100A12 226202.57 21157.16 Paeni_PIH Proteomics
SDCBP 50213.4 4283.095 NPIH Proteomics
SDCBP 77780.78 6725.238 NonPaeni_PIH Proteomics
SDCBP 130499.8 15048.869 Paeni_PIH Proteomics
SERPINB1 166738.39 13430.713 NPIH Proteomics
SERPINB1 224181.28 22991.06 NonPaeni_PIH Proteomics
SERPINB1 623367.36 118273.928 Paeni_PIH Proteomics
SIGLEC14 75642.08 13376.91 NPIH Proteomics
SIGLEC14 85814.32 13300.28 NonPaeni_PIH Proteomics
SIGLEC14 69099.42 6459.969 Paeni_PIH Proteomics
SOD2 216602.91 19426.173 NPIH Proteomics
SOD2 350152.5 32592.274 NonPaeni_PIH Proteomics
SOD2 592462.98 92008.911 Paeni_PIH Proteomics
TAGLN2 49330.14 4441.276 NPIH Proteomics
TAGLN2 88738 13122.68 NonPaeni_PIH Proteomics
TAGLN2 128991.53 16839.534 Paeni_PIH Proteomics
TALDO1 394224.77 31213.484 NPIH Proteomics
TALDO1 397284.78 46011.468 NonPaeni_PIH Proteomics
TALDO1 763613.88 152020.927 Paeni_PIH Proteomics
VIM 212003.12 22419.596 NPIH Proteomics
VIM 236106.62 15654.802 NonPaeni_PIH Proteomics
VIM 329432.96 37277.74 Paeni_PIH Proteomics
YWHAZ 196027.15 19719.259 NPIH Proteomics
YWHAZ 219335.11 23143.789 NonPaeni_PIH Proteomics
YWHAZ 291817.05 34784.541 Paeni_PIH Proteomics
